Researchers are excited about this new drug, a novel dual agonist showing remarkable outcomes in clinical trials for size loss . It acts by targeting both pathways : GLP-1 and GIP, which , when engaged , https://emilyqtvz407628.sharebyblog.com/40657291/this-new-prospect-for-body-reduction